Updated survival outcomes of NEJ005/TCOG0902, a randomized phase II study of concurrent (C) versus sequential alternating (S) gefitinib and chemotherapy in previously untreated non-small cell lung cancer (NSCLC) with sensitive epidermal growth factor receptor (<i>EGFR</i>) mutations.
Satoshi Oizumi(Hokkaido University), Makoto Maemondo(Miyagi Prefectural Hospital Organization), Koichi Hagiwara(Jichi Medical University), Akihiko Gemma(Nippon Medical School), Hiroshi Isobe, Kunihiko Kobayashi(Saitama International Medical Center), Koichi Minato, Ichiro Kinoshita(Hokkaido University), Akira Inoue(Tohoku University Hospital), Toshiyuki Harada(Hokkaido hospital), Yoshiki Demura(Ishikawa Prefectural Central Hospital), Shunichi Sugawara(Sendai Kousei Hospital), Satoshi Morita(Kyoto University), Yuka Fujita, Minoru Kurihara(Japan Clinical Cancer Research Organization), Kazuhiko Ito(Niigata City General Hospital), Toshihiro Nukiwa(Tohoku University), Satoshi Watanabe(Niigata University Medical and Dental Hospital), Masao Harada(Shikoku Cancer Center)
Cited by 4
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
|The Lancet|2021|1.5k
Nrf2 Redirects Glucose and Glutamine into Anabolic Pathways in Metabolic Reprogramming
|Cancer Cell|2012|1.4k
Double-blind, Placebo-controlled Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
|American Journal of Respiratory and Critical Care Medicine|2005|953